Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_assertion type Assertion NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_head.
- NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_assertion description "[The ruthenium polypyridyl complexes [Ru(dip)2(bpy/bpy-2-nitroIm)](2+) (dip = 4,7-diphenyl-1,10-phenanthroline, bpy = 2,2'-bipyridine, bpy-2-nitroIm = 4-[3-(2-nitro-1H-imidazol-1-yl)propyl]) were found to be ca. ten times more cytotoxic against breast cancer (4T1) and human lung adenocarcinoma epithelial cells (A549) than a well-known anticancer drug, cisplatin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_provenance.
- NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_assertion evidence source_evidence_literature NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_provenance.
- NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_assertion SIO_000772 25711770 NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_provenance.
- NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_assertion wasDerivedFrom befree-2016 NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_provenance.
- NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_assertion wasGeneratedBy ECO_0000203 NP1265989.RA6DxdhS9wSP7g-2N9hNfe45fk_IwCoqLcV8q2kXfCGYE130_provenance.